The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis

Journal of Bone and Mineral Metabolism

Volumn 27, Issue 4, 2009, Pages 471-478

  Yan, Yuxiang ^a   Wang, Wei ^a   Zhu, Hanmin ^b   Li, Mei ^c   Liu, Jianli ^d   Luo, Bangyao ^e   Xie, Haibao ^f   Zhang, Guangjian ^g   Li, Fuobao ^h  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^f ZHEJIANG HOSPITAL   (China)

^g FUDAN UNIVERSITY   (China)

^h SUN YAT SEN UNIVERSITY   (China)

Author keywords

Alendronate; BMD; Bone markers; Chinese

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CALCICHEW D; CALCIUM; CREATININE; PHOSPHORUS; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FEMUR NECK; GASTROESOPHAGEAL REFLUX; GREATER TROCHANTER; HAND FRACTURE; HIP; HUMAN; LESSER TROCHANTER; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PELVIS FRACTURE; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VOMITING; WRIST FRACTURE;

AGED; ALENDRONATE; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY; CHINA; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; FEMUR; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PELVIC BONES; PEPTIDES; TREATMENT OUTCOME;

EID: 67749092926     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-009-0057-7     Document Type: Article

References (35)

1. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy JAMA 285 785 795
2. W Gu KL Rennie X Lin Y Wang Z Yu 2007 Differences in bone mineral status between urban and rural Chinese men and women Bone 41 393 399 (Pubitemid 47208630)
3. XG Cheng DZ Yang Q Zhou TJ Zhuo HC Zhang J Xiang HF Wang PZ Ou JL Liu L Xu GY Huang QR Huang HS Barden LS Weynand KG Faulkner XW Meng 2007 Age-related bone mineral density, bone loss rate, prevalence of osteoporosis, and reference database of women at multiple centers in China J Clin Densitom 10 276 284 (Pubitemid 47198535)
4. Z Liu J Piao L Pang X Qing S Nan Z Pan Y Guo X Wang F Li J Liu X Cheng 2002 The diagnostic criteria for primary osteoporosis and the incidence of osteoporosis in China J Bone Miner Metab 20 181 189 (Pubitemid 41184331)
5. Silvano Adami 2007 Bisphosphonate antifracture efficacy Bone 41 S8 S15
6. Montvale (2001) Fosamax prescribing information. Physicians' desk reference at, 55th edn. Medical Economics Co, New Jersey
7. T Mersfelder JA Armitstead MF Ivey M Cedars 1999 A medication use evaluation of alendronate: compliance with administration guidelines Pharm Pract Manag Q 18 50 58
8. D Kendler AW Kung G-H Fuleihan JG González González KA Gaines N Verbruggen 2004 Patients with osteoporosis prefer once weekly to once daily dosing with alendronate Maturitas 48 243 251 (Pubitemid 38781149)
9. JA Simon EM Lewiecki ME Smith RA Petruschke L Wang JJ Palmisano 2002 Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study Clin Ther 24 1871 1886 (Pubitemid 35440956)
10. Rizzoli R, Greenspan SL, Bone G 3rd, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC 2nd, Kaur A, Peverly CA, Orloff JJ, Alendronate Once-Weekly Study Group (2002) Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17:1988-1996 (Pubitemid 35239200)
11. T Schnitzer HG Bone G Crepaldi S Adami M McClung 2000 Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis Aging (Milano) 12 1 12 (Pubitemid 30136655)
12. ZQ Cheng W Yin JY Fan TY Ma 2002 The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis Acta Acad Med Sinica 24 306 309
13. B Cryer N Binkley C Simonelli EM Lewiecki F Lanza E Chen RA Petruschke C Mullen AE de Papp 2005 A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis Am J Geriatr Pharmacother 3 127 136 (Pubitemid 41644451)
14. National Osteoporosis Foundation (2003) Physician's guide to prevention and treatment of osteoporosis [Online]. Available at: http://www.nof.org/-vti- bin/shtml.dll/physguide/index. htm
15. L Yan A Prentice B Zhou H Zhang X Wang DM Stirling A Laidlaw Y Han A Laskey 2002 Age- and gender-related differences in bone mineral status and biochemical markers of bone metabolism in Northern Chinese men and women Bone 30 412 415 (Pubitemid 34150165)
16. Y Liu JY Fan 2002 Measuranents of osteocalcin and cross-linked N-telopeptide of type I collagen in postmenopausal osteoporosis J Tianjin Med Univ 13 511 516
17. S Uchida T Taniguchi T Shimizu T Kakikawa K Okuyama M Okaniwa H Arizono K Nagata AC Santora M Shiraki M Fukunaga T Tomomitsu Y Ohashi T Nakamura 2005 Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study J Bone Miner Metab 23 382 388 (Pubitemid 41223801)
18. AY Ho AW Kung 2005 Efficacy and tolerability of alendronate once-weekly in Asian postmenopausal osteoporotic women Ann Pharmacother 39 1428 1433 (Pubitemid 41197121)
19. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE; Fosamax Actonel Comparison Trial Investigators (2004) Treatment with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized, double-blind study. J Bone Miner Res 20: 141-151
20. M Luckey R Kagan S Greenspan H Bone RD Kiel J Simon J Sackarowitz J Palmisano E Chen RA Petruschke AE de Papp 2004 Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis Menopause 11 405 415 (Pubitemid 40362164)
21. Hee-Jeong Choi Jee-Aee Imb Sang-Hwan Kim 2008 Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss Maturitas 60 170 176
22. Hochberg MC, Ross PD, Black D, Fracture Intervention Trial Research Group. (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 42:1246-1254 (Pubitemid 29268962)
23. SR Cummings L Palermo KE Ensrud 2000 Are nonresponders responding? Presented at the Annual Meeting of the American Society of Bone and Mineral Research J Bone Miner Res 15 S144
24. Granney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C; Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group (2002) Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23: 570-578 (Pubitemid 34925651)
25. JA Kanis A Oden O Johnell F Caulin H Bone JM Alexandre E Abadie F Lekkerkerker 2002 Uncertain future of trials in osteoporosis Osteoporos Int 13 443 449 (Pubitemid 34742201)
26. P Ammann R Rizzoli 2003 Bone strength and its determinants Osteoporos Int 14 Suppl 3 S13 S18
27. Chestnut CH III, Rosen CJ, for the Bone Quality Discussion Group (2001) Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 16:2163-2172 (Pubitemid 33104707)
28. ST Cummings DB Karpf F Harris HK Genant K Ensurd AZ LaC-roix 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs Am J Med 12 281 289 (Pubitemid 34219441)
29. RD Wasnich PD Miller 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density J Clin Endocrinol Metab 85 231 236 (Pubitemid 32268819)
30. MC Hochberg S Greensapn RD Wasnich P Miller DE Thompson PD Ross 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents J Clin Endocrinol Metab 87 1586 1592 (Pubitemid 34615244)
31. P Gerdhem KK Ivaska SL Alatalo JM Halleen J Hellman A Isaksson K Pettersson HK Väänänen K Akesson KJ Obrant 2004 Biochemical markers of bone metabolism and prediction of fracture in elderly women J Bone Miner Res 19 386 393 (Pubitemid 38787393)
32. S Sarkar JY Reginster GG Crans A Diez-Perez KV Pinette PD Delmas 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk J Bone Miner Res 19 394 401 (Pubitemid 38787394)
33. P Garnero E Hausherr MC Chapuy C Marcelli H Grandjean C Muller C Cormier G Bréart PJ Meunier PD Delmas 1996 Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study J Bone Miner Res 11 1531 1538 (Pubitemid 26331009)
34. R Eastell I Barton RA Hannon A Chines P Garnero PD Delmas 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J Bone Miner Res 18 1051 1056 (Pubitemid 37294942)
35. NH Bjarnason S Sarkar T Duong B Mitlak PD Delmas C Christiansen 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis Osteoporos Int 12 922 930 (Pubitemid 34001005)